Clinical Trial Detail

NCT ID NCT03121352
Title Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.